Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

189 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Multivariable model development and internal validation for prostate cancer specific survival and overall survival after whole-gland salvage Iodine-125 prostate brachytherapy.
Peters M, van der Voort van Zyp JR, Moerland MA, Hoekstra CJ, van de Pol S, Westendorp H, Maenhout M, Kattevilder R, Verkooijen HM, van Rossum PS, Ahmed HU, Shah TT, Emberton M, van Vulpen M. Peters M, et al. Among authors: van rossum ps, van de pol s, van der voort van zyp jr, van vulpen m. Radiother Oncol. 2016 Apr;119(1):104-10. doi: 10.1016/j.radonc.2016.02.002. Epub 2016 Feb 17. Radiother Oncol. 2016. PMID: 26897512 Free article.
Decline of dose coverage between intraoperative planning and post implant dosimetry for I-125 permanent prostate brachytherapy: comparison between loose and stranded seed implants.
Moerland MA, van Deursen MJ, Elias SG, van Vulpen M, Jürgenliemk-Schulz IM, Battermann JJ. Moerland MA, et al. Among authors: van deursen mj, van vulpen m. Radiother Oncol. 2009 May;91(2):202-6. doi: 10.1016/j.radonc.2008.09.013. Epub 2008 Oct 22. Radiother Oncol. 2009. PMID: 18950884
Conventional versus automated implantation of loose seeds in prostate brachytherapy: analysis of dosimetric and clinical results. In regard to Genebes et al.
Moerland MA, Maenhout M, van der Voort van Zyp JR, Noteboom JL, Eppinga WS, van Vulpen M, Monninkhof EM, Verkooijen HM. Moerland MA, et al. Among authors: van der voort van zyp jr, van vulpen m. Int J Radiat Oncol Biol Phys. 2014 Jun 1;89(2):436-7. doi: 10.1016/j.ijrobp.2014.02.020. Epub 2014 May 5. Int J Radiat Oncol Biol Phys. 2014. PMID: 24837898 No abstract available.
Focal salvage iodine-125 brachytherapy for prostate cancer recurrences after primary radiotherapy: a retrospective study regarding toxicity, biochemical outcome and quality of life.
Peters M, Maenhout M, van der Voort van Zyp JR, Moerland MA, Moman MR, Steuten LM, van Deursen MJ, van Vulpen M. Peters M, et al. Among authors: van deursen mj, van der voort van zyp jr, van vulpen m. Radiother Oncol. 2014 Jul;112(1):77-82. doi: 10.1016/j.radonc.2014.06.013. Epub 2014 Jul 3. Radiother Oncol. 2014. PMID: 24998704
Diffusion-weighted magnetic resonance imaging for the prediction of pathologic response to neoadjuvant chemoradiotherapy in esophageal cancer.
van Rossum PS, van Lier AL, van Vulpen M, Reerink O, Lagendijk JJ, Lin SH, van Hillegersberg R, Ruurda JP, Meijer GJ, Lips IM. van Rossum PS, et al. Among authors: van hillegersberg r, van lier al, van vulpen m. Radiother Oncol. 2015 May;115(2):163-70. doi: 10.1016/j.radonc.2015.04.027. Epub 2015 May 19. Radiother Oncol. 2015. PMID: 26002307
Urethral and bladder dosimetry of total and focal salvage Iodine-125 prostate brachytherapy: Late toxicity and dose constraints.
Peters M, van der Voort van Zyp J, Hoekstra C, Westendorp H, van de Pol S, Moerland M, Maenhout M, Kattevilder R, van Vulpen M. Peters M, et al. Among authors: van de pol s, van vulpen m, van der voort van zyp j. Radiother Oncol. 2015 Nov;117(2):262-9. doi: 10.1016/j.radonc.2015.08.018. Epub 2015 Sep 5. Radiother Oncol. 2015. PMID: 26349590
189 results